Literature DB >> 23968672

Cost-control mechanisms in Canadian private drug plans.

Jillian Kratzer1, Kimberlyn McGrail, Erin Strumpf, Michael R Law.   

Abstract

Approximately 68% of Canadians receive prescription drug coverage through an employer-sponsored private plan. However, we have very limited data on the structure of these plans. This study aims to identify and describe the use of cost-control mechanisms in private drug plans in Canada and describe what private coverage looks like for the average Canadian. Using 2010 data from over 113,000 different private drug plans, provided by Applied Management Consultants, we determined the overall use of key cost-control measures, and the cost-control tools that appear to be gaining currency compared to a report on benefits coverage in 1998. We found that the use of common cost-control measures is relatively low among Canadian private benefits programs. Co-insurance is much more common in private coverage plans than co-payments. Deductibles are uncommon in Canada and, when in place, are very small. The use of annual and lifetime maximums is increasing. Canadian private benefits programs use few cost-control measures to respond to increasing costs, particularly in comparison to their public counterparts. These results suggest there are ample opportunities for greater efficiency in private sector drug coverage plans.
Copyright © 2013 Longwoods Publishing.

Mesh:

Substances:

Year:  2013        PMID: 23968672      PMCID: PMC3999546     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  12 in total

1.  Medication costs, adherence, and health outcomes among Medicare beneficiaries.

Authors:  Ramin Mojtabai; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2003 Jul-Aug       Impact factor: 6.301

2.  Costs of health care administration in the United States and Canada.

Authors:  Steffie Woolhandler; Terry Campbell; David U Himmelstein
Journal:  N Engl J Med       Date:  2003-08-21       Impact factor: 91.245

3.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Authors:  Jamie R Daw; Steven G Morgan
Journal:  Health Policy       Date:  2011-10-05       Impact factor: 2.980

4.  Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.

Authors:  Marie-Pascale Pomey; Steve Morgan; John Church; Pierre-Gerlier Forest; John N Lavis; Tom McIntosh; Neale Smith; Jennifer Petrela; Elisabeth Martin; Sarah Dobson
Journal:  J Health Polit Policy Law       Date:  2010-10       Impact factor: 2.265

5.  Benefit design and specialty drug use.

Authors:  Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

6.  Income-based drug coverage in British Columbia: the impact on private and public expenditures.

Authors:  Steve Morgan; Lixiang Yan
Journal:  Healthc Policy       Date:  2006-11

7.  Ontario's law curbing the cost of generic drugs sparks changes for pharmacies and other Canadian buyers.

Authors:  Ann Silversides
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

8.  Cardiovascular morbidity associated with nonadherence to statin therapy.

Authors:  David F Blackburn; Roy T Dobson; James L Blackburn; Thomas W Wilson
Journal:  Pharmacotherapy       Date:  2005-08       Impact factor: 4.705

9.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Authors:  R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

Review 10.  Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

Authors:  Dana P Goldman; Geoffrey F Joyce; Yuhui Zheng
Journal:  JAMA       Date:  2007-07-04       Impact factor: 56.272

View more
  12 in total

1.  The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada.

Authors:  Jillian Kratzer; Lucy Cheng; Sara Allin; Michael R Law
Journal:  Healthc Policy       Date:  2015-05

2.  Should national pharmacare apply a value-based insurance design?

Authors:  Kai Yeung; Steven G Morgan
Journal:  CMAJ       Date:  2019-07-22       Impact factor: 8.262

3.  The increasing inefficiency of private health insurance in Canada.

Authors:  Michael R Law; Jillian Kratzer; Irfan A Dhalla
Journal:  CMAJ       Date:  2014-03-24       Impact factor: 8.262

4.  The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.

Authors:  Michael R Law; Lucy Cheng; Ashra Kolhatkar; Laurie J Goldsmith; Steven G Morgan; Anne M Holbrook; Irfan A Dhalla
Journal:  CMAJ Open       Date:  2018-02-05

5.  Patterns of borrowing to finance out-of-pocket prescription drug costs in Canada: a descriptive analysis.

Authors:  Ashra Kolhatkar; Lucy Cheng; Steven G Morgan; Laurie J Goldsmith; Irfan A Dhalla; Anne M Holbrook; Michael R Law
Journal:  CMAJ Open       Date:  2018-11-19

Review 6.  Pharmacare in Canada: The paediatric perspective.

Authors:  Tom McLaughlin; Geert 't Jong; Andrea Gilpin; Charlotte Moore Hepburn
Journal:  Paediatr Child Health       Date:  2020-03-13       Impact factor: 2.253

7.  Impact of brand drug discount cards on private insurer, government and patient expenditures.

Authors:  Michael R Law; Fiona K I Chan; Mark Harrison; Heather C Worthington
Journal:  CMAJ       Date:  2019-11-11       Impact factor: 8.262

8.  Inequity in insurance coverage for prescription drugs in New Brunswick, Canada.

Authors:  Busola Ayodele; Elaine Xiaoyu Guo; Arthur Sweetman; G Emmanuel Guindon
Journal:  Can J Public Health       Date:  2022-04-29

Review 9.  Universal prescription drug coverage in Canada: Long-promised yet undelivered.

Authors:  Steven G Morgan; Katherine Boothe
Journal:  Healthc Manage Forum       Date:  2016-10-15

Review 10.  Canada's universal health-care system: achieving its potential.

Authors:  Danielle Martin; Ashley P Miller; Amélie Quesnel-Vallée; Nadine R Caron; Bilkis Vissandjée; Gregory P Marchildon
Journal:  Lancet       Date:  2018-02-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.